

	(ENGLISH OFFICE TRANSLATION)
INNKALLING TIL ORDINÆR GENERALFORSAMLING LYTIX BIOPHARMA AS (organisasjonsnummer 985 889 635)	NOTICE OF ANNUAL GENERAL MEETING LYTIX BIOPHARMA AS (company registration number 985 889 635)
Den 21. april 2022 kl. 13.00 avholdes det ordinær generalforsamling i Lytix Biopharma AS (" Selskapet "), i Selskapets lokaler i Sandakerveien 138, 0484 Oslo, Norge.	21 April 2022 at 13:00 Hours (CEST), an ordinary general meeting in Lytix Biopharma AS (the " Company ") will take place, at the Company's offices in Sandakerveien 138, 0484 Oslo, Norway.
Generalforsamlingen vil bli åpnet av styrets leder, Gert Wilhelm Munthe, som vil opprette fortegnelse over møtende aksjeeiere og fullmakter.	The general meeting will be opened by the chairman of the board of directors, Gert Wilhelm Munthe. The chairman will register the attendance of shareholders present and proxies.
Følgende saker er på agendaen:	The following matters are on the agenda:
1 VALG AV MØTELEDER	1 ELECTION OF A PERSON TO CHAIR THE MEETING
2 VALG AV ÉN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN SAMMEN MED MØTELEDEREN	2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES TOGETHER WITH THE CHAIR OF THE MEETING
3 GODKJENNELSE AV INNKALLING OG DAGSORDEN	3 APPROVAL OF NOTICE AND AGENDA
Styret foreslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Innkallingen og dagsorden godkjennes."</i>	<i>"The notice and the agenda are approved."</i>
4 GODKJENNELSE AV ÅRSREGNSKAPET OG ÅRSBERETNINGEN FOR REGNSKAPSÅRET 2021	4 APPROVAL OF THE ANNUAL ACCOUNTS AND THE ANNUAL REPORT FOR THE FINANCIAL YEAR 2021
Styrets forslag til årsregnskap og årsberetning for regnskapsåret 2021, samt revisjonsberetningen, er vedlagt som <u>Vedlegg 1</u> til innkallingen.	The board of director's proposal for the annual accounts and the annual report for the financial year 2021, including the auditor's report, are attached to this notice as Appendix 1.
Styret foreslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Årsregnskapet og årsberetningen for regnskapsåret 2021 godkjennes"</i> .	<i>"The annual accounts and the annual report for the financial year 2021 is approved"</i> .
Videre foreslår styret at generalforsamlingen treffer følgende vedtak om utdeling av utbytte:	Further, the board of directors proposes that the general meeting passes the following resolution with respect to distribution of dividend:
<i>"Det utdeles ikke utbytte for regnskapsåret 2021."</i>	<i>"Dividends will not be distributed for the financial year 2021."</i>
5 GODKJENNELSE AV REVISORS GODTGJØRELSE	5 APPROVAL OF THE AUDITOR'S REMUNERATION
Styret forslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Godtgjørelse til revisor for revisjon og revisjonsrelaterte tjenester for regnskapsåret 2021 godkjennes etter regning."</i>	<i>"Remuneration to the auditor for audit and audit related costs for the financial year 2021 based on invoice is approved."</i>
6 HONORAR TIL STYRETS MEDLEMMER	6 REMUNERATION TO THE MEMBERS OF THE BOARD OF DIRECTORS
Opsjonsavtalen som har fungert som godtgjørelse til styrelederposisjonen strekker seg tilbake til historiske omstendigheter og har tjent sin hensikt. Valgkomitéen foreslår en tilpasning av godtgjørelsespraksis blant alle styremedlemmer. For å reflektere endrede forventninger og forpliktelser til et styre i et børsnotert selskap, foreslår valgkomitéen å øke styrehonoraret. For perioden fra generalforsamlingen 2021 frem til generalforsamlingen 2022 foreslår komitéen at styrets leder skal motta NOK 360.000 og	The option agreement that has served as remuneration for the position of chairman of the board goes back to historical circumstances and has served its purpose. The Nomination Committee proposes an adaptation of remuneration practice among all board members. In order to reflect changed expectations and obligations to a board of directors in a listed company, the nomination committee proposes to increase the board fee. For the period from the general meeting

styremedlemmene skal motta NOK 240.000. Videre foreslår valgkomitéen å holde godtgjørelsesnivået uendret for perioden frem til generalforsamlingen 2023.	2021 until the general meeting 2022, the committee proposes that the chairman of the board shall receive NOK 360,000 and the board members shall receive NOK 240,000. Furthermore, the nomination committee proposes to keep the remuneration level unchanged for the period up to the general meeting in 2023.
I samsvar med valgkomitéens innstilling foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til styrets medlemmer:	In accordance with the nomination committee's proposal, the board of directors propose that the general meeting resolves the following regarding remuneration to the members of the board of directors:
<i>"Generalforsamlingen godkjenner følgende honorar til styrets medlemmer for perioden fra ordinær generalforsamling i 2021 til ordinær generalforsamling i 2022:</i>	<i>"The general meeting approves the following remuneration to the members of the board of directors for the period from the annual general meeting in 2021 to the annual general meeting in 2022:</i>
<ul style="list-style-type: none"> • Styrets leder, Gert Wilhelm Munthe, skal motta NOK 360.000. 	<ul style="list-style-type: none"> • The chairman of the board of directors, Gert Wilhelm Munthe, shall receive NOK 360,000.
<ul style="list-style-type: none"> • Styremedlemmene skal motta NOK 240.000 hver <ul style="list-style-type: none"> ○ Marie-Louise Fjällskog ○ Brynjar Forbergskog ○ Kjetil Hestdal ○ Jayson Rieger ○ Evelina Vågesjö" 	<ul style="list-style-type: none"> • The Board members shall receive NOK 240,000 each <ul style="list-style-type: none"> ○ Marie-Louise Fjällskog ○ Brynjar Forbergskog ○ Kjetil Hestdal ○ Jayson Rieger ○ Evelina Vågesjö"
7 HONORAR TIL MEDLEMMER AV VALGKOMITEEN	7 REMUNERATION TO THE MEMBERS OF THE NOMINATION COMMITTEE
Valgkomitéen ble valgt for perioden fra generalforsamlingen i 2021 til generalforsamlingen i 2022. I oktober 2021 ba Lars Bakklund om å bli løst fra vervet som leder i komitéen og at han ikke skulle få noen kompensasjon for perioden frem til fratredelsen.	The nomination committee was elected for the period from the general meeting in 2021 to the general meeting in 2022. In October 2021, Lars Bakklund asked to be released from his duties as chairman of the committee and that he should not receive any compensation for the period until his resignation.
Ingen erstatter ble nominert på det tidspunktet, så komitéen har bestått av følgende medlemmer:	No replacement was nominated at the time, so the committee has consisted of the following members:
<ul style="list-style-type: none"> ○ Per Erik Sørensen ○ Lise von Tangen Jordan ○ Steinar Thoresen 	<ul style="list-style-type: none"> ○ Per Erik Sørensen ○ Lise von Tangen Jordan ○ Steinar Thoresen
Komitéhonorarene foreslås justert for å gjenspeile den reelle arbeidsmengden og forpliktelsen som kreves. For perioden fra generalforsamlingen 2021 frem til generalforsamlingen 2022 foreslår valgkomitéen at komitéens leder skal motta NOK 60.000 og komitéens medlemmer NOK 50.000 hver.	The committee fees are proposed to be adjusted to reflect the actual workload and commitment required. For the period from the general meeting 2021 until the general meeting 2022, the nomination committee proposes that the chair of the committee receives NOK 60,000 and the members receive NOK 50,000 each.
Videre foreslår valgkomitéen at godtgjørelsesnivået holdes uendret for perioden frem til generalforsamlingen 2023.	Furthermore, the nomination committee proposes that the level of remuneration be kept unchanged for the period up to the general meeting in 2023.
I samsvar med valgkomiteens innstilling foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til valgkomitéens medlemmer:	In accordance with the nomination committee's recommendation, the board proposes that the general meeting make the following resolution on the remuneration of the nomination committee's members:
<i>"Generalforsamlingen godkjenner følgende honorar til valgkomitéens medlemmer for perioden fra ordinær generalforsamling i 2021 til ordinær generalforsamling i 2022:</i>	<i>"The general meeting approves the following remuneration to the members of the board of directors for the period from the annual general meeting in 2021 to the annual general meeting in 2022:</i>
<ul style="list-style-type: none"> • Valgkomitéens leder, Lars Bakklund, trakk fra seg fra vervet i oktober 2021 og skal ikke motta noen kompensasjon. 	<ul style="list-style-type: none"> • The chairman of the nomination committee, Lars Bakklund, resigned in October 2021 and will not receive any compensation.
<ul style="list-style-type: none"> • Medlemmene i valgkomitéen skal motta NOK 50.000 hver <ul style="list-style-type: none"> ○ Per Erik Sørensen ○ Lise von Tangen Jordan ○ Steinar Thoresen" 	<ul style="list-style-type: none"> • The members of the nomination committee shall receive NOK 50,000 each <ul style="list-style-type: none"> ○ Per Erik Sørensen ○ Lise von Tangen Jordan ○ Steinar Thoresen"

<p>8 STYREFULLMAKT - KAPITALFORHØYELSE</p>	<p>8 BOARD AUTHORIZATION – SHARE CAPITAL INCREASE</p>
<p>8.1 Styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram</p>	<p>8.1 Board authorization to increase the share capital in connection to the Company's incentive program</p>
<p>Bakgrunn</p>	<p>Background</p>
<p>Styret har i henhold til generalforsamlingens vedtak 24. juni 2020 en fullmakt til å forhøye aksjekapitalen med inntil NOK 370.000 knyttet til Selskapets opsjonsprogram for styrets leder, styremedlemmer, ansatte og andre nøkkelpersoner.</p> <p>Denne fullmakten er gyldig frem til ordinær generalforsamling i 2022, dog ikke lenger enn til 24. juni 2022.</p>	<p>Pursuant to the resolution of the Annual General Meeting on 24 June 2020, the Board has an authorization to increase the share capital by up to NOK 370,000 related to the Company's option program for the Chairman of the Board, board members, employees and other key personnel.</p> <p>This authorization is valid until the annual general meeting in 2022, but no longer than until 24 June 2022.</p>
<p>8.1.1 Ny styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram</p>	<p>8.1.1 New board authorization to increase the share capital in connection to the Company's option programs</p>
<p>Styret foreslår at generalforsamlingen fatter følgende vedtak om ny styrefullmakt knyttet til Selskapets opsjonsprogram:</p>	<p>The Board of Directors proposes that the general meeting passes the following resolution on a new board authorization related to the Company's option program:</p>
<p><i>(i) I henhold til aksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital med inntil NOK 506.642,00 knyttet til Selskapets opsjonsprogram til styreformann, styremedlemmer, ansatte og andre nøkkelpersoner.</i></p> <p><i>(ii) Fullmakten gjelder frem til ordinær generalforsamling i 2024 er avholdt, dog ikke lenger enn til 21. april 2024.</i></p> <p><i>(iii) Aksjeeiernes fortrinnsrett til nye aksjer etter allmenn-aksjeloven § 10-4 skal kunne fravikes.</i></p> <p><i>(iv) Fullmakten omfatter også kapitalforhøyelse mot innskudd i andre eiendeler enn penger, herunder kapitalforhøyelse ved motregning.</i></p>	<p><i>(i) Pursuant to section 10-14 of the Norwegian Companies Act, the board is authorized to increase the Company's share capital by up to NOK 506,642.00 in connection with the Company's option program for the chairman, board members, employees and other key persons.</i></p> <p><i>(ii) The authorization is valid until the annual general meeting in 2024 has been held, but no longer than until 21 April 2024.</i></p> <p><i>(iii) The shareholders' pre-emptive right to new shares pursuant to the Public Limited Liability Companies Act § 10-4 shall be waived.</i></p> <p><i>(iv) The authorization also includes a capital increase against deposits in assets other than cash, including a capital increase by set-off.</i></p>
<p>8.2 Styrefullmakt til generell kapitalforhøyelse</p>	<p>8.2 Board authorization to increase the share capital</p>
<p>Bakgrunn</p>	<p>Background</p>
<p>Styret ble på generalforsamling den 7. juni 2021 tildelt en fullmakt til generelt å forhøye aksjekapitalen, i en eller flere omganger, med inntil NOK 375.000. Denne fullmakten gjelder fra generalforsamlingens beslutning og frem til ordinær generalforsamling i 2022, dog senest til 30. juni 2022.</p> <p>For at Selskapet skal kunne ha mulighet til å gjennomføre fremtidige kapitalforhøyelser for å utstede nye aksjer på en rask og smidig måte, foreslås det at styret gis fullmakt til å forhøye aksjekapitalen med inntil NOK 400.683,10 (tilsvarende ca. 10 % av Selskapets aksjekapital), ved utstedelsen av opptil 4.006.831,00 nye aksjer.</p>	<p>At the general meeting on 7 June 2021, the board was authorized to generally increase the share capital, in one or more rounds, by up to NOK 375,000. This authorization is valid from the decision of the general meeting until the annual general meeting in 2022, however no later than 30 June 2022.</p> <p>In order for the Company to be able to carry out future capital increases in order to issue new shares in a quick and flexible manner, it is proposed that the Board is authorized to increase the share capital by up to NOK 400,683.10 (corresponding to approximately 10% of the Company's share capital), with the issue of up to 4,006,831.00 new shares.</p>
<p>8.2.1 Ny styrefullmakt til generell kapitalforhøyelse</p>	<p>8.2.1 New board authorization for general capital increase</p>
<p>Styret foreslår at generalforsamlingen fatter følgende vedtak om ny styrefullmakt:</p>	<p>The board proposes that the general meeting adopts the following resolution on a new board authorization:</p>
<p><i>(i) I henhold til aksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital, i en eller flere omganger, med inntil NOK 400.683,19.</i></p>	<p><i>(i) Pursuant to section 10-14 of the Norwegian Companies Act, the board is authorized to increase the Company's share capital, in one or more rounds, by up to NOK 400,683.19.</i></p>

<p>(ii) Fullmakten gjelder frem til ordinær generalforsamling i 2024 er avholdt, dog ikke lenger enn til 21. april 2024.</p> <p>(iii) Aksjonærenes fortrinnsrett til de nye aksjene kan fravikes, jf. aksjeloven § 10-5, jf. § 10-4.</p> <p>(iv) Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter aksjeloven § 13-5</p> <p>(v) Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger.</p>	<p>(ii) The authorization is valid until the annual general meeting in 2024 has been held, but no longer than until 21 April 2024.</p> <p>(iii) The shareholders' preferential right to the new shares may be deviated from, cf. Section 10-5, cf. Section 10-4 of the Companies Act.</p> <p>(iv) The authorisation does not include an increase in share capital through merger in accordance with Section 13-5 of the Companies Act.</p> <p>(v) The authorisation does not include an increase in share capital by contribution in kind.</p>
<p>9 VALG AV STYRE OG VALGKOMITÉ</p>	<p>15 ELECTION OF BOARD OF DIRECTORS AFTER THE LISTING</p>
<p>Det sittende styret ble på OGF 2021 valgt inn til og med Selskapets ordinære generalforsamling i 2023.</p> <p>Valgkomitéen har avgitt sin innstilling om at nåværende medlemmer av valgkomitéen fortsetter sine verv, med Per Erik Sørensen som komitéens leder – ref vedlegg 2, frem til og med selskapets ordinære generalforsamling i 2023.</p>	<p>At Ordinary General Assembly 2021, the current Board of Directors was elected until the Company's annual general meeting in 2023.</p> <p>The Nomination Committee has submitted its recommendation that the current members of the Nomination Committee continue their duties (with Per Erik Sørensen as the Chair) - ref Appendix 2 up to and including the Company's annual general meeting in 2023.</p>
<p>Styret foreslår at følgende personer velges til valgkomiteen for perioden frem til Selskapets neste ordinære generalforsamling:</p>	<p>The board proposes that the general meeting adopts the following resolution about the Nomination Committee:</p>
<ul style="list-style-type: none"> o Per Erik Sørensen (leder) o Lise von Tangen Jordan o Steinar Thoresen 	<ul style="list-style-type: none"> o Per Erik Sørensen (Chair) o Lise von Tangen Jordan o Steinar Thoresen
<p style="text-align: center;">* * *</p>	<p style="text-align: center;">* * *</p>
<p>Dersom du/dere ønsker å delta på generalforsamlingen ber vi om at vedlagte møteseddel sendes til post@lytixbiopharma.com innen 19. april 2022, kl.16.00.</p> <p>Aksjeeiere som ikke ønsker å delta på generalforsamlingen henstilles om å fylle ut vedlagte fullmaktsskjema og sende det til post@lytixbiopharma.com innen 19. april 2022, kl. 16.00.</p>	<p>Shareholders who want to attend the general meeting are requested to complete the attendance slip and send it by e-mail to post@lytixbiopharma.com latest April 19, 2022 at 16.00 CET.</p> <p>Shareholders who do not wish to attend the general meeting are recommended to complete the enclosed power of attorney and return to post@lytixbiopharma.com, within April 19, 2022 at 16.00 CET.</p>
<p style="text-align: center;">* * *</p>	<p style="text-align: center;">* * *</p>
<p>6 April 2022</p>	
<p>På vegne av styret / On behalf of the Board of Directors of Lytix Biopharma AS</p> <p>Gert Wilhelm Munthe <i>Styrets leder / Chairman of the board</i></p>	
<p>Vedlegg:</p> <ol style="list-style-type: none"> 1 Årsregnskap, årsberetning og revisjonsberetning for 2021 2 Innstilling fra nominasjonskomiteen 3 Møte- og fullmakts-seddel 	<p>Appendices:</p> <ol style="list-style-type: none"> 1 Annual accounts, annual report and auditors report for 2021 2 Motion from the Nomination Committee 3 Attendance slip and Power of attorney

Vedlegg 2 / Appendix 2

2022 Nomination & Compensation Committee – Lytix Biopharma AS

The Committee mandate is restricted to:

- A. Nominate board candidates and candidates for the Nomination & Compensation Committee for the shareholders on the General Assembly to vote on.
- B. Give advice on potential demands for employee board representation to the Assembly.
- C. Oversee and propose board remuneration levels.

The Nomination and Compensation Committee (the "N&C Committee") is also asked by the Board to nominate candidates for the N&C Committee and to suggest remuneration levels for the committee.

In connection with the upcoming General Meeting of Lytix Biopharma AS ("Lytix" or the "Company"), the N&C Committee has been asked to review the board composition of the Company.

1. BOARD COMPOSITION

According to the minutes from the 2021 general assembly the current Board is elected for a period reaching forward to the 2023 assembly.

The Board of Directors will accordingly continue with the following composition: *Gert Wilhelm Munthe (Chair), Marie-Louise Fjällskog, Kjetil Hestdal, Evelina Vågesjö, Jayson Rieger and Brynjar Forbergskog*

The N&C Committee has not identified immediate demands for employee board representation.

2. OVERSEE AND PROPOSE BOARD REMUNERATION LEVELS.

The stock option-based remuneration to the Chair Position is reaching back to historical circumstances and have served its purpose. The N&C Committee proposes an alignment of remuneration practices among all Board Members.

To reflect changed expectations and obligations to a board in a publicly listed company, the N&C Committee proposes to increase the board remuneration. For the period to the AGM 2022, the N&C Committee proposes that the Chairman of the Board shall receive NOK 360.000 and the Board members shall receive NOK 240.000. Further, the N&C Committee proposes to keep the remuneration levels unchanged for the period to the AGM 2023.

Remuneration to board members can, as of the next pay-out, be fully or partially converted to company shares according to price tags regulated in the power of attorney given to the board by the general assembly.

3. NOMINATION & COMPENSATION COMMITTEE.

The current N&C committee was elected for a period of one period until the general assembly 2022.

In October 2021, Lars Bakklund asked to be released from his duties as chairman in the N&C Committee and that he should not receive any compensation for the period until resignation. No replacement was nominated at that time.

The N&C committee proposes that the members are re-elected for a period to the AGM 2023. Then, for the next period, the N&C Committee will consist of the following members: Lise von Tangen-Jordan, Steinar Thoresen and Per Erik Sørensen (Chair)

Committee fees are proposed adjusted to reflect the true workload and the commitment required. For the period to the AGM 2022, the N&C Committee proposes that the Chairman of the N&C Committee shall receive NOK 60.000 and the N&C Committee members shall receive NOK 50.000. Due to the resignation of Lars Bakklund, he will not receive compensation for the period he chaired the N&C Committee. Further, the N&C Committee proposes to keep the remuneration levels unchanged for the period to the AGM 2023.

Copenhagen, March 25th, 2022

Steinar Thoresen

Lise von Tangen-Jordan

Per Erik Sørensen

Vedlegg 3 / Appendix 3

PÅMELDING – ORDINÆR GENERALFORSAMLING 21. APRIL 2022 I LYTIX BIOPHARMA AS

Melding om at De vil delta i den ordinære generalforsamlingen gis ved å benytte denne møteseddel. Det bes om at signert skjema sendes til post@lytixbiopharma.com senest den 19. april 2022, kl. 16:00. Dersom De etter påmelding skulle bli forhindret fra å møte, kan skriftlig og datert fullmakt leveres på den ordinære generalforsamlingen.

Undertegnede vil møte på den ordinære generalforsamlingen i Lytix Biopharma AS den 21. april og (sett kryss):

- Avgi stemme for mine/våre aksjer
- Avgi stemme for aksjer ifølge vedlagte fullmakt(er)

Navn på aksjonær / selskap (blokkbokstaver): _____

Antall egne aksjer: _____

Antall aksjer som eventuelt representeres etter fullmakt: _____

dato

sted

aksjonærens underskrift

REGISTRATION – ANNUAL GENERAL MEETING APRIL 21, 2022 IN LYTIX BIOPHARMA AS

Notice of attendance at the Annual General Meeting is asked to be sent via this attendance slip. Kindly submit the signed notice by email to post@lytixbiopharma.com no later than April 19, 2022, 16:00 CET. If you are unable to attend after you have registered, a written and dated proxy can be submitted at the annual general meeting.

The undersigned will attend the Annual general meeting of Lytix Biopharma AS April 21, 2022 and (tick-off):

- Vote for my/our shares
- Vote for shares pursuant to enclosed proxy(ies)

Shareholder's name / company name (capital letters): _____

Number of own shares: _____

Number of shares represented by proxy: _____

Date

Place

Shareholder's signature

LYTIX BIOPHARMA AS
FULLMAKTSSKJEMA TIL ORDINÆR GENERALFORSAMLING DEN 21. april 2022

Aksjeeiere som ikke selv møter på den ordinære generalforsamlingen i Lytix Biopharma AS den 21. april 2022, bes om å fylle ut denne fullmakten og sende den **per e-post til post@lytixbiopharma.com**.

Fullmaktsskjema bes sendes slik at det er kommet frem til Selskapet **senest den 19. april 2022 kl. 16:00**.

Undertegnede gir herved (sett kryss):

Styrets leder, Gert Wilhelm Munthe, eller den han bemyndiger

fullmakt til å møte og representere meg/oss på den ordinære generalforsamlingen i Lytix Biopharma AS den 21. april 2022. Dersom det er sendt inn fullmakt uten avkryssing ovenfor, anses fullmakten gitt til styrets leder, Gert Wilhelm Munthe, eller den han bemyndiger.

Stemmegivningen skal skje i henhold til instruksjonene nedenfor. Merk at **dersom det ikke er krysset av i rubrikkene nedenfor, vil dette anses som en instruks om å stemme "for" forslagene i innkallingen**, likevel slik at fullmektigen avgjør stemmegivningen i den grad det blir fremmet forslag i tillegg til, til erstatning for, eller som endring i forslagene i innkallingen.

	Sak	For	Mot	Avstår	Fullmektig avgjør
1	Valg av møteleder				
2	Valg av én person til å medundertegne protokollen sammen med møtelederen				
3	Godkjenning av innkalling og dagsorden				
4	Godkjenning av årsregnskapet og årsberetningen for regnskapsåret 2021				
5	Godkjenning av revisors godtgjørelse				
6	Honorar til styrets medlemmer				
7	Honorar til medlemmer av valgkomitéen				
8.1	Styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram				
8.2	Styrefullmakt til generell kapitalforhøyelse				
9	Valg av styre og valgkomité				

Aksjeeierens navn: _____
(Vennligst benytt blokkbokstaver)

Antall aksjer: _____

_____ Dato _____ Sted _____ Aksjeeierens underskrift

Dersom aksjeeieren er et selskap, eller annen juridisk enhet, skal dokumentasjon i form av firmaattest, og eventuelt fullmakt, vedlegges fullmakten.

LYTIX BIOPHARMA AS
PROXY FORM TO THE ANNUAL GENERAL MEETING ON 21 APRIL 2022

Shareholders who will not attend the annual general meeting on 21 April 2022 in person, are asked to complete this proxy form and return it **per e-mail to post@lytixbiopharma.com**.

The proxy form should be received by the Company **no later than 19 April 2022 at 16:00 hours (CEST)**.

The undersigned hereby grants (please tick):

The chairperson of the board, Gert Wilhelm Munthe, or the person he appoints,

power of attorney to attend and vote for my/our shares at the annual general meeting of Lytix Biopharma AS to be held on 21 April 2022. If the proxy form is submitted without ticking of the box above, the proxy will be deemed to have been given to the chairperson of the board of directors, Gert Wilhelm Munthe, or the person he appoints.

The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the proxy holder determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice.

	Item	In favour	Against	Abstain	At the proxy's discretion
1	Election of a person to chair the meeting				
2	Election of a person to co-sign the minutes together with the chair of the meeting				
3	Approval of the notice and the agenda				
4	Approval of the annual accounts and the annual report for the financial year 2021				
5	Approval of the auditor's remuneration				
6	Remuneration to the members of the board of directors				
7	Remuneration to the members of the nomination committee				
8.1	Board authorization to increase the share capital in connection to the Company's incentive program				
8.2	Board authorization to increase the share capital				
9	Election of board of directors and nomination committee				

The shareholder's name: _____
(Please use capital letters)

Number of shares: _____

Date

Place

Shareholder's signature

If the shareholder is a legal entity, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.